Progression of Late-Onset Stargardt Disease
Investigative Ophthalmology & Visual Science2016Vol. 57(13), pp. 5186–5186
Citations Over TimeTop 10% of 2016 papers
Stanley Lambertus, Moritz Lindner, Nathalie M. Bax, Matthias M. Mauschitz, Jennifer Nadal, Matthias Schmid, Steffen Schmitz-Valckenberg, Anneke I. den Hollander, Bernhard H. F. Weber, Frank G. Holz, Gert Jan van der Wilt, Monika Fleckenstein, Carel B. Hoyng, for the Foveal sparing Atrophy Study Team (FAST)
Abstract
We show that RPE atrophy represents a robust biomarker to monitor disease progression in future therapeutic trials. In contrast, the variability in terms of the course of visual acuity was high.
Related Papers
- → Clinical and Genetic Spectrum of Stargardt Disease in Argentinean Patients(2021)13 cited
- → Genotype–Phenotype Association in ABCA4-Associated Retinopathy(2023)5 cited
- → Stargardt Disease Caused by a Rare Combination of Double Homozygous Mutations(2013)5 cited
- → Stargardt Disease(2014)1 cited
- → ABCA4- Related Retinopathies in Lebanon: a novel mutation and significant heterogeneity(2023)